ANVS
Annovis Bio, Inc.
Biotechnology
Market Cap$65M
5Y Perf.-45.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ANVS vs PRTA
Revenue, margins, valuation, and 5-year total return — side by side.
PRTA
Prothena Corporation plc
Biotechnology
Market Cap$602M
5Y Perf.+4.9%
ANVS vs PRTA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ANVS | PRTA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $65M | $602M |
| Revenue (TTM) | $0.00 | $10M |
| Net Income (TTM) | $-29M | $-244M |
| Gross Margin | — | -208.6% |
| Operating Margin | — | -22.5% |
| Forward P/E | — | 45.3x |
| Total Debt | $0.00 | $14M |
| Cash & Equiv. | $19.53B | $308M |
ANVS vs PRTA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ANVS
PRTA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Annovis Bio, Inc. (ANVS) | 100 | 54.1 | -45.9% |
| Prothena Corporatio… (PRTA) | 100 | 104.9 | +4.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ANVS vs PRTA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ANVS leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Prothena Corporation plc is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
ANVS
Annovis Bio, Inc.
The Growth Play
ANVS carries the broadest edge in this set and is the clearest fit for growth exposure.
- EPS growth 99.9%
- 100.4% revenue growth vs PRTA's -92.8%
- 0.0% margin vs PRTA's -25.2%
Best for: growth exposure
PRTA
Prothena Corporation plc
The Income Pick
PRTA is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.96
- -70.8% 10Y total return vs ANVS's -75.0%
- Lower volatility, beta 0.96, Low D/E 4.9%, current ratio 7.72x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ANVS | 100.4% revenue growth vs PRTA's -92.8% |
| Quality / Margins | ANVS | 0.0% margin vs PRTA's -25.2% |
| Stability / Safety | PRTA | Beta 0.96 vs ANVS's 2.16 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ANVS | +66.7% vs PRTA's +52.1% |
| Efficiency (ROA) | ANVS | -0.5% ROA vs PRTA's -62.0% |
ANVS vs PRTA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
ANVS vs PRTA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRTALAGGINGANVS
ANVSAnnovis Bio, Inc.
1leads
PRTAProthena Corporation …
2leads
6 Total Categories
CATEGORYLEADERvs ANVSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PRTA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ANVS6/6
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
PRTA2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PRTA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
PRTA and ANVS operate at a comparable scale, with $10M and $0 in trailing revenue.
| Metric | ANVSAnnovis Bio, Inc. | PRTAProthena Corporat… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $10M |
| EBITDAEarnings before interest/tax | -$30M | -$216M |
| Net IncomeAfter-tax profit | -$29M | -$244M |
| Free Cash FlowCash after capex | -$853M | -$168M |
| Gross MarginGross profit ÷ Revenue | — | -2.1% |
| Operating MarginEBIT ÷ Revenue | — | -22.5% |
| Net MarginNet income ÷ Revenue | — | -25.2% |
| FCF MarginFCF ÷ Revenue | — | -17.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -99.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +16.7% | +63.0% |
PRTA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — ANVS and PRTA each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ANVSAnnovis Bio, Inc. | PRTAProthena Corporat… |
|---|---|---|
| Market CapShares × price | $65M | $602M |
| Enterprise ValueMkt cap + debt − cash | -$19.5B | $308M |
| Trailing P/EPrice ÷ TTM EPS | -1.71x | -2.47x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 45.32x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 62.15x |
| Price / BookPrice ÷ Book value/share | 0.00x | 2.15x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — ANVS and PRTA each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ANVS leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
ANVS delivers a -0.7% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-73 for PRTA. On the Piotroski fundamental quality scale (0–9), ANVS scores 2/9 vs PRTA's 1/9, reflecting mixed financial health.
| Metric | ANVSAnnovis Bio, Inc. | PRTAProthena Corporat… |
|---|---|---|
| ROE (TTM)Return on equity | -0.7% | -73.0% |
| ROA (TTM)Return on assets | -0.5% | -62.0% |
| ROICReturn on invested capital | — | -21.0% |
| ROCEReturn on capital employed | -0.3% | -47.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | — | 0.05x |
| Net DebtTotal debt minus cash | -$19.5B | -$294M |
| Cash & Equiv.Liquid assets | $19.5B | $308M |
| Total DebtShort + long-term debt | $0 | $14M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
ANVS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — ANVS and PRTA each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRTA five years ago would be worth $4,725 today (with dividends reinvested), compared to $1,095 for ANVS. Over the past 12 months, ANVS leads with a +66.7% total return vs PRTA's +52.1%. The 3-year compound annual growth rate (CAGR) favors ANVS at -45.5% vs PRTA's -47.4% — a key indicator of consistent wealth creation.
| Metric | ANVSAnnovis Bio, Inc. | PRTAProthena Corporat… |
|---|---|---|
| YTD ReturnYear-to-date | -34.2% | +21.5% |
| 1-Year ReturnPast 12 months | +66.7% | +52.1% |
| 3-Year ReturnCumulative with dividends | -83.8% | -85.5% |
| 5-Year ReturnCumulative with dividends | -89.1% | -52.7% |
| 10-Year ReturnCumulative with dividends | -75.0% | -70.8% |
| CAGR (3Y)Annualised 3-year return | -45.5% | -47.4% |
Evenly matched — ANVS and PRTA each lead in 3 of 6 comparable metrics.
Risk & Volatility
PRTA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PRTA is the less volatile stock with a 0.96 beta — it tends to amplify market swings less than ANVS's 2.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRTA currently trades 95.6% from its 52-week high vs ANVS's 43.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ANVSAnnovis Bio, Inc. | PRTAProthena Corporat… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.16x | 0.96x |
| 52-Week HighHighest price in past year | $5.50 | $11.69 |
| 52-Week LowLowest price in past year | $1.42 | $4.32 |
| % of 52W HighCurrent price vs 52-week peak | +43.6% | +95.6% |
| RSI (14)Momentum oscillator 0–100 | 59.6 | 60.4 |
| Avg Volume (50D)Average daily shares traded | 887K | 475K |
PRTA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ANVSAnnovis Bio, Inc. | PRTAProthena Corporat… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $19.00 |
| # AnalystsCovering analysts | — | 28 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRTA leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). ANVS leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallProthena Corporation plc (PRTA)Leads 2 of 6 categories
Loading custom metrics...
ANVS vs PRTA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ANVS or PRTA a better buy right now?
Analysts rate Prothena Corporation plc (PRTA) a "Buy" — based on 28 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ANVS or PRTA?
Over the past 5 years, Prothena Corporation plc (PRTA) delivered a total return of -52.
7%, compared to -89. 1% for Annovis Bio, Inc. (ANVS). Over 10 years, the gap is even starker: PRTA returned -70. 8% versus ANVS's -75. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ANVS or PRTA?
By beta (market sensitivity over 5 years), Prothena Corporation plc (PRTA) is the lower-risk stock at 0.
96β versus Annovis Bio, Inc. 's 2. 16β — meaning ANVS is approximately 125% more volatile than PRTA relative to the S&P 500.
04Which is growing faster — ANVS or PRTA?
On earnings-per-share growth, the picture is similar: Annovis Bio, Inc.
grew EPS 99. 9% year-over-year, compared to -99. 6% for Prothena Corporation plc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ANVS or PRTA?
Annovis Bio, Inc.
(ANVS) is the more profitable company, earning 0. 0% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANVS leads at 0. 0% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — PRTA leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ANVS or PRTA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ANVS or PRTA better for a retirement portfolio?
For long-horizon retirement investors, Prothena Corporation plc (PRTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
96)). Annovis Bio, Inc. (ANVS) carries a higher beta of 2. 16 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRTA: -70. 8%, ANVS: -75. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ANVS and PRTA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.